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THROMBOSIS AND HEMOSTASIS
EphB2 regulates contact-dependent and contact-independent signaling
to control platelet function
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Alexander R. Stainer, Neline Kriek, Leonardo A. Moraes, and Jonathan M. Gibbins
Institute for Cardiovascular and Metabolic Research, School of Biological Sciences, University of Reading, Reading, United Kingdom
Key Points
• EphB2 regulates initial platelet
activation in the absence of





The Eph kinases, EphA4 and EphB1, and their ligand, ephrinB1, have been previously
reported tobepresent inplateletswhere theycontribute to thrombusstability.Although
thrombus formation allows for Eph-ephrin engagement and bidirectional signaling, the
importance specifically of Eph kinase or ephrin signaling in regulating platelet function
remained unidentified. In the present study, a genetic approach was used in mice
to establish the contribution of signaling orchestrated by the cytoplasmic domain of
EphB2 (a newly discovered Eph kinase in platelets) in platelet activation and thrombus
formation. We conclude that EphB2 signaling is involved in the regulation of thrombus
formation and clot retraction. Furthermore, the cytoplasmic tail of this Eph kinase
regulates initial platelet activation in a contact-independent manner in the absence of
Eph-ephrin ligation between platelets. Together, these data demonstrate that EphB2 signaling not only modulates platelet function
within a thrombus but is also involved in the regulation of the function of isolated platelets in a contact-independent manner. (Blood.
2015;125(4):720-730)
Introduction
Sustained contact-dependent signaling by integrin aIIbb3 in platelets
is believed to be important to ensure thrombus stability, and may con-
trol the size and multilayered architecture of a thrombus as it grows,
contracts, and adopts a conformation to ensure cessation of blood loss.1
The repertoire of receptors that may support contact-dependent sig-
naling within a thrombus extends beyond integrin aIIbb3, and in-
corporates activators of platelet function such as Eph kinases2 and
their cell-surface ligands, the ephrins, and negative regulators such
as platelet endothelial cell adhesion molecule-1 (PECAM-1),3,4 junc-
tional adhesion molecule A (JAM-A),5,6 and endothelial cell-
speciﬁc adhesion molecule (ESAM).7 Sustained platelet signaling
within thrombi has also been recently shown to involve intercellular
signaling through gap junctions.8-10 Knowledge of the signaling
mechanisms that platelets use within a thrombus may therefore offer
new perspectives on strategies to prevent thrombotic disease. This led
us to explore the mechanisms that allow a newly identiﬁed platelet
Eph kinase, EphB2, to control platelet function.
Eph kinases comprise a family of cell-surface receptor tyrosine
kinases that play roles in development of the central nervous system
and vasculature,11-13 and their ligands, ephrins, are integral membrane
or transmembrane proteins. Eph kinases are classiﬁed as EphA (bind
ephrin A) and EphB (bind ephrin B) family members, although more
promiscuous cross-family interactions have been reported.14 Ephrin
A family members are glycosylphosphatidylinositol (GPI) anchored
and ephrin B family members possess a transmembrane domain.
Eph kinase ligation occurs in trans, that is, the receptor on one cell
binds a ligand on the opposing cell thereby transmitting signals in
both directions (forward signaling by Eph kinases and reverse sig-
naling by ephrins).11 The presence of EphA4, EphB1, and ephrinB1
in human platelets has been reported,15 where forced clustering of
EphA4 or ephrinB1 resulted in cytoskeletal rearrangements, ﬁbrino-
gen binding, and granule secretion. EphA4 was also reported to form
complexes in platelets with tyrosine kinases Fyn, Lyn, and cell
adhesion molecule, L1. Blockade of Eph/ephrin interactions resulted
in reduced platelet activation.15 Further studies have emphasized the
role of EphA4 in the regulation of integrin aIIbb3-mediated outside-in
signaling controlling platelet spreading and clot retraction, and provide
compelling evidence for the role of Eph kinases and ephrins in the
activation of platelets.2,15-17 How they contribute, and whether this is
consistent with a role in the initiation of sustained platelet signaling
within a thrombus, however, remains unknown.
Because ephrinB1 was the only Eph ligand identiﬁed in platelets,
we sought to explore the potential role of EphB2, one of its principal
receptors that we report to be present in platelets. Given the complex-
ities of bidirectional signaling, we used a strategy that would enable us
to ask whether signaling elicited through the cytoplasmic domain of
EphB2 controls platelet function. This was achieved using transgenic
mice (EphB2LacZ) expressingEphB2with the cytoplasmic tail replaced
withb-galactosidase rendering it signaling defectivewhilemaintaining
capability for ephrin binding. We demonstrate that the EphB2-mediated
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signaling is not only involved in thrombus formation where sustained
bidirectional signalingmay occur but also in initial platelet activation
in the absence of cell-cell contact. Furthermore, we report that the
EphB2 intracellular domain plays important roles in the regulation of
phosphoinositide 3-kinase (PI3K) and integrin aIIbb3-mediated sig-
naling, thereby controlling platelet function.
Methods
The preparation ofwashedplatelets, immunoblotting, immunoprecipitation and
platelet functional assays such as aggregation, dense granule secretion, ﬁbrin-
ogen binding, P-selectin exposure, calciummobilization, clot retraction, platelet
spreading, thrombus formation, and tail bleeding were performed as described
previously.8,9,18,19 Detailed materials and methods are provided in supplemen-
tal Methods (see supplemental Data available on the BloodWeb site).
Generation of EphB2LacZ mice
EphB2LacZmice were developed by replacing the intracellular region includ-
ing kinase domain, sterile alphamotif (SAM) and PDZmotifs (ie, after 621 aa
at the N terminus including extracellular, transmembrane and juxtamembrane
domains) by a full-length b-galactosidase gene as reported previously20,21
and maintained on a C57BL6 genetic background. Littermate controls were
used in all experiments. All animals were used following appropriate approval
from the University of Reading Local Ethics Review Panel and a license from
the British Home Ofﬁce.
Results
Characterization of EphB2LacZ mouse platelets
The presence of EphB2 was conﬁrmed in control mice platelets by
immunoblot analysis (Figure 1A). The fusion of b-galactosidase with
EphB2 in transgenic mice resulted in a protein that was larger than
native EphB2, and detected with an apparent molecular mass of
;200 kDa (Figure 1A). The presence of b-galactosidase fused with
EphB2was conﬁrmed by immunoblot analysis (Figure 1B). The ligand,
ephrinB1, was also detected in EphB2LacZ and control platelets at
similar levels (Figure 1C). Platelet numbers in EphB2LacZ were sim-
ilar to those in control mice and their cellular morphology (size and
granule numbers, established by transmission electron microscopy)
was indistinguishable (data not shown). The level of P-selectin expres-
sion in EphB2LacZ platelets was similar to control platelets (Figure 1D) as
were integrinaIIbb3 (Figure 1E), integrina2b1 (Figure 1F), glycoprotein
VI (GPVI) (Figure 1G) and GPIba (Figure 1H).
Removal of EphB2 intracellular region does not affect
ephrinB1 activation
Binding of EphB2 to its ligand, ephrinB1, triggers clustering and ini-
tiates signaling and phosphorylation of speciﬁc intracellular amino
acid residues on each.11Washed platelets fromEphB2LacZ and control
mice were activated and aggregated using cross-linked collagen-related
peptide (CRP-XL) (0.5 mg/mL) and lysed prior to the immuno-
precipitation of ephrinB1 followed by immunoblotting with an anti-
phosphotyrosine antibody. Platelet activation was associated with the
phosphorylation of ephrinB1 that was maintained in EphB2LacZ
platelets (Figure 1I). These data indicate that replacement of the
EphB2 cytoplasmic tail does not diminish clustering and signaling
through ephrinB1 and suggests that the receptor is present at func-
tional levels on EphB2LacZ platelets.
Replacement of EphB2 intracellular region abrogates
platelet activation
To analyze the importance of the cytoplasmic tail of EphB2 for
platelet activation, aggregation assays were performed using washed
platelets obtained from EphB2LacZ and control mice using optical
aggregometry. Collagen (1mg/mL)–induced aggregationwas reduced
by;85%(at 5minutes) inEphB2LacZplatelets comparedwithcontrols
(Figure 2A-B), and the inhibitory effects were overcome partially when
a higher concentration (5 mg/mL) of collagen was used (Figure 2C-D).
These data suggest that the reduced activation in EphB2LacZ platelets is
not due to the developmental defects but reﬂects the importance of
EphB2 in the regulation of platelet function. Because collagen binds
GPVIand integrina2b1onplatelets, aGPVI-selectiveagonist,CRP-XL,
was used in aggregation assays to determine whether reduction in
aggregation occurred through the modulation of GPVI-dependent
signaling. CRP-XL (0.5 mg/mL)–induced platelet aggregation was
reduced by;60% (Figure 2E-F), although the level of inhibitionwas
diminished at higher concentration (Figure 2G-H) (at 5 minutes) in
EphB2LacZ platelets. EphB2 functionswere not restricted to theGPVI
pathway, as thrombin (0.1 U/mL [Figure 2I-J])–induced platelet
Figure 1. Characterization of EphB2LacZ platelets.
The presence of EphB2 (A), b-galactosidase (B), and
ephrinB1 (C) was confirmed in control (a) and EphB2LacZ
(b) mouse platelets by immunoblot analysis. Similarly,
the expression level of P-selectin was measured in con-
trol (a) and EphB2LacZ (b) mouse platelets by immuno-
blot analysis (D). The expression levels of aIIbb3 (E), a2b1
(F), GPVI (G), and GPIba (H) were analyzed on control
and EphB2LacZ platelets by flow cytometry. Data repre-
sent mean (of median fluorescence intensity) 6 SD
(n 5 4, control and EphB2LacZ mice). (I) ephrinB1 was im-
munoprecipitated from control and EphB2LacZ platelets
following stimulation with CRP-XL (0.5 mg/mL) and ana-
lyzed for its phosphorylation using anti-phosphotyrosine
antibody by immunoblotting. The blots are representa-
tive of 3 separate experiments. CRP-XL, cross-linked
collagen-related peptide; GP, glycoprotein; SD, standard
deviation.
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aggregation (which activates platelets through G-protein–coupled
protease-activated receptors) was also diminished in EphB2LacZ
platelets although, again, the inhibitory effects were partially over-
come when a higher concentration of thrombin (0.2 U/mL) was used
(Figure 2K-L).
Platelet aggregation requires the conformational modulation of
integrin aIIbb3 to enable ﬁbrinogen binding.22 Thus, ﬁbrinogen bind-
ingwasmeasured inEphB2LacZandcontrol platelets (usingwholeblood)
upon stimulationwithCRP-XLor thrombinbyﬂowcytometry.Reduced
ﬁbrinogen binding was observed in EphB2LacZ platelets compared with
controls upon stimulation with CRP-XL (Figure 3A-B) and thrombin
(Figure 3C-D). To analyze whether EphB2-mediated signaling is
involved in the control of a-granule secretion in platelets, P-selectin
exposure was measured inEphB2LacZ and control mouse whole blood
using ﬂow cytometry. CRP-XL (0.5mg/mL and 1mg/mL)–induced
(Figure 3E-F) and thrombin (0.1 U/mL and 0.2 U/mL)–induced
(Figure 3G-H) P-selectin exposure was reduced signiﬁcantly in
EphB2LacZ platelets. The use of whole blood and through gating
individual platelets usingﬂow cytometry enabled the study of EphB2
on platelets in the absence of Eph-ephrin interactions. It also pre-
vented the potential complexities thatwould be introduced during the
preparation of washed platelets although the results are consistent as
observed for aggregation assays. Similar toa-granule secretion, dense
granule secretionmeasured upon stimulationwithCRP-XL(1mg/mL)
inEphB2LacZ plateletswas reduced (Figure 3I-J). These results support
the notion that EphB2 is involved in the regulation of agonist-induced
platelet activation throughmodulation of integrinaIIbb3-mediated
inside-out signaling and granule secretion.
Rap1b is a member of the Ras superfamily of proteins23,24 and is
involved in the regulation of integrin aIIbb3.25,26 Because ﬁbrinogen
binding was affected in EphB2LacZ platelets, Rap1b activation was
analyzed. Resting and CRP-XL (0.5 mg/mL)–stimulated platelets were
lysed and guanosine triphosphate (GTP)–bound Rap1b precipitated
using Ral guanine nucleotide dissociation stimulator (Ral-GDS)-
agarose beads. CRP-XL–activated control platelets showed activa-
tion of Rap1b, whereas Rap1b activation was reduced in platelets
obtained from EphB2LacZ mice (Figure 3K), indicating that the
EphB2 intracellular domain may signal to Rap1b in the regulation of
integrin aIIbb3 function.
EphB2 regulates platelet calcium mobilization and
PI3K signaling
Elevation of intracellular calcium levels in platelets upon exposure to
agonists plays a major role in the regulation of platelet function in-
cluding reorganizationof the actin cytoskeleton,which is necessary for
shape change,27 degranulation, and modulation of integrin aIIbb3
afﬁnity.28 Although the initial acceleration of calcium mobilization
upon stimulationwithCRP-XL (1mg/mL)measured usingﬂow cytom-
etry was not affected by the absence of the EphB2 cytoplasmic tail, the
overall level of calcium releasedwas reduced substantially inEphB2LacZ
platelets (Figure 4A).
EphB2 is reported to recruit and activate Src kinase through tyrosine
phosphorylation at Y605 and Y611 in the juxtamembrane domain.29,30
Because these sites are present in the EphB2 in EphB2LacZ mice, to
understand the impact of the defective receptor on Src activation, the
phosphorylation of Src was explored upon activation of platelets with
CRP-XL (0.5 mg/mL). The phosphorylation level of Src at Y418 in
EphB2LacZ platelets was unaltered (Figure 4B). To explore whether
the activation of molecules that mediate initial GPVI signaling was
Figure 2. Defective aggregation of EphB2LacZ platelets. Platelet aggregation was recorded for 5 minutes by optical aggregometry using washed platelets obtained from
control and EphB2LacZ mice following stimulation with collagen (1 mg/mL [A-B] or 5 mg/mL [C-D]), CRP-XL (0.5 mg/mL [E-F] or 1 mg/mL [G-H]), and thrombin (0.1 U/mL [I-J]
or 0.2 U/mL [K-L]). Data represent mean 6 SD (n 5 3). The level of aggregation obtained with control platelets at 5 minutes was taken as 100% (Student t test: *P # .05,
**P # .01, and ***P # .001).
diminished in EphB2LacZ platelets, phosphorylation levels of Lyn
(Y396), Syk, and linker for activation of T cells (LAT) were assessed
using immunoblot analysis. CRP-XL (0.5mg/mL)–induced phosphor-
ylation of Lyn (Y396), Syk, and LAT was unaffected in EphB2LacZ
platelets, indicating that EphB2 is not involved in GPVI proximal
signaling (Figure 4B). Phospholipase Cg2 (PLCg2) and phospho-
lipase Cb3 (PLCb3) are activated downstream of GPVI and
Gq-mediated G-protein–coupled receptor (GPCR) signaling path-
ways, respectively, and responsible for the liberation of inositol
trisphosphate (IP3) that releases calcium from intracellular stores.
Because calcium mobilization was reduced in EphB2LacZ platelets,
CRP-XL (0.5 mg/mL)–induced tyrosine phosphorylation of PLCg2
and thrombin (0.1U/mL)–induced tyrosine phosphorylation ofPLCb3
were analyzed in washed platelets by immunoblot analysis. Both
PLCg2 and PLCb3 were found to be phosphorylated in control plate-
lets upon stimulation with CRP-XL and thrombin, respectively. The
phosphorylation level of PLCg2 (Figure 4C) and PLCb3 (Figure 4D)
was reduced inEphB2LacZ platelets 90 seconds following stimulation.
Similarly, CRP-XL (0.5mg/mL)–stimulated (Figure 4E) and thrombin
(0.1U/mL)–stimulated (Figure 4F) phosphorylation of protein kinase B
(PKB/AKT), a downstream effector of PI3K, was found to be reduced
inEphB2LacZ platelets comparedwith controls. Together, these data
point toward reduced PI3K signaling in EphB2LacZ platelets.
Because receptor proximal signaling was relatively unaffected
in EphB2LacZ platelets, experiments were performed to determine
whether its mode(s) of action lies further downstream through
bypassing receptor proximal signaling and directly activating platelets
using a calcium ionophore. Ionomycin (5 and 10 mM)–induced
ﬁbrinogen binding was reduced signiﬁcantly in EphB2LacZ mice
platelets (Figure 4G-H), indicating that EphB2 is involved in
the regulation of downstream signaling that modulates platelet
function.
EphB2 regulates platelet integrin signaling
The integrinaIIbb3 transduces signals into the cell-triggering platelet
spreading and in the latter phase of thrombus formation to regulate clot
retraction.31 To determine whether the EphB2 is involved in the regu-
lation of integrinaIIbb3-mediated outside-in signaling, clot retraction
wasmeasured. Although the initial clot formationwas unchanged, clot
retraction was found to be reduced in EphB2LacZ platelets at 2 hours
(Figure 5A-B).
Association of myosin with cytoplasmic region of b3 is required
for clot retraction.32,33 Hence, the association of myosin with the
integrin b3 tail in EphB2LacZ and control platelets upon stimulation
with 0.5mg/mL CRP-XLwas analyzed. Resting and activated plate-
lets were lysed and myosin was coimmunoprecipitated with b3.
Detection with a myosin-speciﬁc antibody demonstrated the associ-
ation of myosin with b3 in activated control platelets and a reduced
level of binding in EphB2LacZ platelets (Figure 5C). Myosin binding
requires the phosphorylation of 2 tyrosine residues (Y773 and Y785
in humans [Y747 andY759 inmice]) in theb3 cytoplasmic domain32
and mutation of either residue retards the retraction of blood clots in
mice.34 Consistent with reduced clot retraction and retarded myosin
binding, the phosphorylation of b3 at Y747 was reduced by ;70%
in EphB2LacZ platelets upon stimulation with CRP-XL compared
Figure 3. EphB2 signaling regulates initial platelet 
activation. CRP-XL (0.5 mg/mL [A] or 1 mg/mL [B])
and thrombin-induced fibrinogen binding (0.1 U/mL [C]
or  0.2 U/mL [D]) were measured in control  and  EphB2LacZ 
mouse whole blood by flow cytometry. Similarly,
CRP-XL (0.5 mg/mL [E] or 1 mg/mL [F]) and thrombin
(0.1 U/ml [G] or 0.2 U/ml [H])-induced P-selectin exposure
were measured in control and EphB2LacZ mouse whole
blood by flow cytometry. ATP release was measured
as a marker for dense granule secretion in washed 
platelets upon stimulation with 1 mg/mL CRP-XL (I-J).
The level of fibrinogen binding or P-selectin exposure
or ATP release (at 5 minutes) obtained in control
was taken as 100% to calculate the percentage of re-
duction. Data represent mean 6 SD (n 5 4) (Student
t test: *P # .05 and **P # .01). (K) Rap1b-GTP was 
precipitated from control and EphB2LacZ resting and 
stimulated platelets with CRP-XL (0.5 mg/mL) and 
analyzed by immunoblotting using a Rap1b antibody.
The blot is representative of 3 separate experiments. ATP, 
adenosine triphosphate; GTP, guanosine triphosphate.
Figure 4. EphB2 influences calcium mobilization and PI3K signaling. (A) Fluo4-NW–labeled control and EphB2LacZ mouse whole blood was stimulated with 1 mg/mL
CRP-XL and the intracellular calcium levels measured by flow cytometry. Data represent mean 6 SD (n 5 4). CRP-XL (0.5 mg/mL)–induced phosphorylation of Src (B), Lyn
(B), Syk (B), LAT (B), PLCg2 (C), and AKT (E) was analyzed by immunoblot analysis using phospho-specific antibodies or following immunoprecipitation. Similarly, thrombin
(0.1 U/mL)–induced phosphorylation of PLCb3 (D) and AKT (F) was measured using immunoblot analysis. The protein 14-3-3z was detected as a loading control in all of the
samples. Blots are representative of 3 separate experiments. The level of phosphorylation obtained with control platelets at 90 seconds was taken as 100%. Ionomycin (5 mM
[G] and 10 mM [H])–induced fibrinogen binding was measured in whole blood using flow cytometry. Data represent mean (of median fluorescence intensity) 6 SD (n 5 3)
(Student t test: *P # .01, **P # .01, and ***P # .001). AKT, protein kinase B.
with controls (Figure 5D). Similarly, thrombin (0.1 U/mL)–induced
phosphorylation of b3 was also diminished in EphB2LacZ platelets
(Figure 5D).
Because EphA4 has been reported to physically interact with
integrinb3 in restingandactivatedplatelets,16 the effects of replacement
of the EphB2 intracellular region on its potential ability to associate
with integrin b3 was analyzed. The immunoprecipitation of EphB2
from resting andCRP-XL (0.5mg/mL)–activated platelets from control
mice established that EphB2 physically associates with b3 in platelets,
but levels were diminished in EphB2LacZ platelets (Figure 5E), indi-
cating that the EphB2 cytoplasmic tail may be important for interaction
with integrin b3 and/or subsequent signaling.
EphB2-mediated regulation of integrin b3 function does not
require ephrin interaction
Platelet spreading following adhesion to ﬁbrinogen is controlled by
integrin aIIbb3 outside-in signaling and does not require platelet-
platelet contact. It is possible that defective responses of platelets to
thrombin that is present in clot retraction assays may in part ex-
plain defective clot retraction exhibited by EphB2LacZ platelets. We
therefore explored platelet spreading on ﬁbrinogen where the addition
of other agonists is not required and where cell density was reduced to
prevent cell-cell contact.
Platelets were allowed to spread on ﬁbrinogen-coated cover glass
for 45 minutes and images were obtained following the staining with
Alexa Fluor 488–conjugated phalloidin by confocal microscopy, and
the results revealed that spreading was retarded inEphB2LacZ platelets
(Figure 5F). To analyze different stages of spreading, multiple images
were obtained by differential interference contrast microscopy and
platelets at different stages of spreading counted (stage A includes
platelets adhered; stage B, with ﬁlopodia; stage C, with lamellipodia;
andD, fully spread). Our data suggested that in comparisonwith con-
trol platelets, a large proportion of EphB2LacZ platelets were retarded
at stage Awith only a small percentage of cells progressing to spread
fully at 45 minutes (Figure 5G).
Figure 5. Integrin aIIbb3-mediated outside-in signaling is reduced in EphB2LacZ platelets. (A) The effect of deletion of EphB2 intracellular domains in clot retraction
was analyzed using PRP from control and EphB2LacZ mice for 2 hours. (B) Clot weight measured after 2 hours. Data represent mean 6 SD (n 5 3). (C) Integrin b3 was
immunoprecipitated from resting and CRP-XL (0.5 mg/mL)–stimulated control and EphB2LacZ platelets and analyzed for its association with myosin by immunoblot analysis.
(D) Phosphorylation of integrin b3 in resting and CRP-XL (0.5 mg/mL)– or thrombin (0.1 U/mL)–activated control and EphB2LacZ platelets was analyzed using phospho-specific
integrin b3 antibody for pY773. The protein 14-3-3z was analyzed as a protein loading control by immunoblot analysis. (E) b3 integrin was coimmunoprecipitated with EphB2 in
control and EphB2LacZ platelets, and analyzed for its association by immunoblot. Immunoblots shown are representative of 3 separate experiments. Data represent mean 6 SD
(n 5 3) and the level of phosphorylation obtained in the control (activated) samples was taken as 100%. (F) Washed platelets obtained from control and EphB2LacZ mice were
allowed to spread on fibrinogen-coated cover glass for 45 minutes prior to staining with Alexa Fluor 488 phalloidin and analyzed by confocal microscopy. Images are representative
of 3 separate experiments. (G) Multiple images obtained by differential interference contrast microscopy were analyzed by counting numbers of platelets in various stages of
spreading using Image J software. P values shown are as calculated by Student t test: *P # .05, **P # .01, and ***P # .001. PRP, platelet-rich plasma.
EphB2 cytoplasmic tail regulates thrombus formation
and hemostasis
Because platelet aggregation, calciummobilization, granule secretion,
and clot retraction were reduced in EphB2LacZ platelets, we hypoth-
esized that EphB2mutationwould inﬂuence thrombus formation. This
was measured in vitro under arterial ﬂow conditions (1000 S21) using
whole ﬂuorescently labeled mouse blood perfused through collagen-
coated biochips. Although similar levels of initial platelet adhesion
were observed in comparison with control mouse blood, thrombus
growth and volume were reduced substantially in EphB2LacZ mouse
blood (Figure 6A-C).
To assess the contributions of EphB2 to thrombus formation in
vivo, laser-induced thrombus formationwas studied in cremastermuscle
arterioles using intravital microscopy. Following laser injury, thrombus
formation was monitored for 3 minutes, and found to be reduced sub-
stantially in EphB2LacZ mice compared with controls (Figure 6D-E).
To assess the importance of the cytoplasmic region of EphB2 for
hemostasis, tail-bleeding assays were performed. The bleeding
time after dissection of 1 mm of tail tip was prolonged substantially
in EphB2LacZ mice compared with controls (Figure 6F). Bleeding
persisted in most EphB2LacZ mice until 10 minutes at which point
assays were terminated.
Discussion
Bidirectional signaling mediated through Eph kinases and their ligands,
ephrins, has been shown to play important roles in the development of
the nervous system,11,35-37 skeletal patterning,38 and angiogenesis.39-42
A surprising role for Eph kinases and their ligands has also been
identiﬁed on circulating platelets during thrombus formation where
sustained Eph-ephrin signaling between platelets was proposed to be
important for the maintenance of thrombus stability.2,15 In the pres-
ent study, we analyzed the function of a newly identiﬁed platelet Eph
kinase, EphB2, and focused on the contribution of its intracellular
region in the stimulation of platelet signaling and activation. The re-
sults of this study suggest that EphB2-derived signaling is important
for the positive regulation of platelet function through control of calcium
mobilization, PI3K, and integrin aIIbb3-mediated signaling (Figure 7).
The use of a genetically modiﬁed mouse in which the intracellular
region of EphB2 was replaced by b-galactosidase enabled us to ex-
plore the functions of the cytoplasmic domains of EphB2 in regulating
platelet function without interfering with its ligand binding. This has
previously been shown to result in defects in pathﬁnding of speciﬁc
axons in the central nervous system, suggesting the importance of the
intracellular domains in EphB2 signaling.20 The previous study also
conﬁrmed the presence of EphB2LacZ fusion protein on the surface of
neuronal cells and where subcellular localization was normal. In our
study, the disruption of the intracellular region of EphB2 was found
to reduce platelet activation, granule secretion, calcium mobilization,
ﬁbrinogen binding, and thrombus formation. These functional defects
were associated with reduced signaling through PI3K and integrin
aIIbb3. The reduction in Rap1b activation in EphB2LacZ platelets
suggests that EphB2 is involved in controlling agonist-induced inside-
out signaling, leading to the activation of integrin aIIbb3.
A principal focus of previous explorations of Eph-ephrin functions
in platelets has been their involvement in sustained signaling between
platelets within a thrombus.2 The functional and signaling defects ob-
servedon individualEphB2LacZmouseplatelets in absenceofEph-ephrin
interactions, for example, while spreading on ﬁbrinogen, ﬁbrinogen
binding, and P-selectin exposure (measured by gating on individual
platelets in ﬂow cytometry analysis), suggest that EphB2-mediated
forward signaling is not entirely dependent on the binding of its
ligand ephrinB1 in the regulation of platelet function. Consistent
with reduced platelet activation, EphB2LacZmouse platelets displayed
diminished phosphorylation of signaling proteins such as AKT and
PLCg2 or PLCb3 upon activation of GPVI or Gq-mediated GPCR
pathways.
The tyrosine phosphorylation of PLCb3 in platelets following
stimulation with thrombin is a novel observation, although tyrosine
phosphorylation sites have been previously identiﬁed in several carci-
noma cell lines using mass spectrometry.43 Several tyrosine phos-
phorylation sites within the sequence of PLCb3 have been predicted,
including a prominent Y855 site that is highly conserved in humans,
mice, and rats. The biological signiﬁcance of PLCb3 tyrosine phos-
phorylation, its regulation, and its impact on enzymatic activity in cell
function are yet to be explored.
The reduction in phosphorylation of AKT and PLCg2 was also
apparent in EphB2LacZ platelets in the presence of agents (such as
EGTA, indomethacin, and apyrase) that block the secondary acti-
vation, indicating that reduced signaling in EphB2LacZ platelets is not
due to the inhibition of secretion of ADP or synthesis of thromboxane
(data not shown). The phosphorylation of signaling proteins proximal
to the GPVI collagen receptor such as Lyn, Syk, and LAT were
unaffected, suggesting that EphB2 may not inﬂuence early signaling
following engagement of GPVI. Reduced ﬁbrinogen binding
observed in EphB2LacZ platelets upon activation with ionomycin
further conﬁrms that EphB2-mediated platelet signaling regulates
downstream signaling of calcium (in addition to the regulation of
calcium mobilization itself) and suggests a complex signaling role.
The tyrosine phosphorylation sites 605 and 611 present in the
juxtamembrane region of EphB2were shown to bind and activate Src
kinase.29,30 Because these sites are intact in the EphB2LacZ platelets,
they may become phosphorylated upon ephrin ligation. Other tyro-
sine phosphorylation sites identiﬁed within the kinase domain such
as 668, 741/751, 779, and 82144 are not present in EphB2LacZ. The
phosphorylation of Y668 in the kinase domain has been suggested to
bind SH2 domain-containing proteins44 and the SAM domain and
PDZ- binding motif to interact with several cytoplasmic proteins. The
absence of these regions in addition to the kinase domain may there-
fore account for reduced platelet function in the current settings. The
retarded functions observed in EphB2LacZ platelets where ephrinB1
binding is potentially maintained (eg, clot retraction assays) suggest
that these functions of EphB2 are not dependent on reverse signaling.
Defective spreading on ﬁbrinogen and clot retraction assessed in
EphB2LacZmouse platelets suggest that EphB2 (particularly the intra-
cellular region) is also involved in the regulation of integrin aIIbb3-
mediated outside-in signaling. Our data indicate that the EphB2
intracellular domain may enhance its physical association with
integrin b3 and contribute to its phosphorylation that in turn
regulates spreading and clot retraction. We cannot rule out that the
reduced PI3K and PLC activities in EphB2LacZ platelets may also be
responsible for the diminished integrin aIIbb3-mediated signaling.
The blockade of EphA4 using recombinant ligands has been reported
to suppress platelet spreading and clot retraction15 and, therefore, in-
teraction with, and regulation of, integrins in platelets may represent a
shared feature of Eph kinase function in these cells. Eph kinases and
ephrins have been widely reported to modulate integrin function,
although speciﬁc effects appear to be cell-type and receptor-type spe-
ciﬁc. For example, activation of EphB1, EphA8, ephrinA2, and
ephrinA5 have been shown to increase integrin afﬁnity and thereby
enhance cell-cell adhesion in endothelial, P19, andHEK-293 cells,45-48
whereas, EphB2, EphA2, and EphA3 regulate cell repulsion/detachment
in PC-3 and HEK-293 cells.49,50 In the present study, we report a role
for EphB2 in regulating integrin aIIbb3 activation and therefore
platelet-platelet adhesion. The means by which this is achieved remain
to be established. In addition to a potential direct signaling role, it is
possible that Eph kinases may form multimeric-protein complexes
with integrin aIIbb3 and other membrane proteins that contribute
to cell adhesion and consequent integrin (outside-in) signaling. In
Figure 6. EphB2 signaling is important for thrombus formation and hemostasis. (A) DiOC6-labeled control or EphB2LacZ mouse blood was perfused over collagen-
coated Vena8 Biochips and thrombus formation monitored for 10 minutes capturing images at every 30 seconds (representative images at different time points shown).
(B) The fluorescence intensity of thrombi obtained from control and EphB2LacZ mice was compared over a 10-minute period. Data represent mean (of sum intensity) 6 SD
(n 5 4). (C) Thrombus intensity obtained in control at 10 minutes was taken as 100% and compared with EphB2LacZ at the same time point. Data represent mean (of sum
intensity) 6 SD (n 5 4). The P values shown in figure are as calculated by 2-way ANOVA (***P # .001). (D) Laser-induced arterial thrombosis was measured in mouse
cremaster muscle arterioles using intravital microscopy and the fluorescence intensity of thrombi (E) was calculated using Slidebook software (version 5.5). Representative
images at different time points and cumulative trace of thrombus formation are shown. Data represent mean6 SD (n5 4 of control and EphB2LacZ mice). The P values shown
in figure are as calculated by 2-way ANOVA (F) Tail bleeding was assessed in control and EphB2LacZ mice by dissection of 1 mm of tail tip and monitoring the time to cessation
of bleeding. Data represent mean6 SD (n5 7 of control and n5 9 EphB2LacZ mice). The P value shown was calculated using the nonparametric Mann-Whitney test. ANOVA,
analysis of variance.
platelets, all 3 Eph kinases identiﬁed to date appear to contribute to
the upregulation of integrin activation, enhance cell-cell adhesion,
and facilitate contact-dependent sustained signaling.
Although it is possible for Eph-ephrin–mediated signaling to con-
tribute within a thrombus once platelet contact has been achieved, our
studies reveal a role for EphB2 earlier in the platelet activation process
and prior to cell contact. It may be speculated that the initial activation
of individual platelets modulates the phosphorylation status of EphB2
and cause the recruitment of effector proteins to the cytoplasmic
domains. The consequence of ﬁbrinogen binding to integrin aIIbb3
may also lead to enhanced clustering of EphB2 because b3 and
EphB2 interact and facilitated Eph-ephrin interactions when the plate-
lets come to closeproximity. In theseways,Ephkinasesmayplay roles
during initial activation in a contact-independent manner and later,
when the Eph-ephrin ligation occurs, contribute to sustained contact-
dependent signaling. As shown previously,2,15 Eph-ephrin ligation and
clustering may induce further activation of platelets through shape
change, degranulation, ﬁbrinogen binding, and strengthening of the
growing thrombus.
The intracellular region of EphB2 incorporates several important
tyrosine phosphorylation sites, a kinase domain, SAM and PDZ-
binding region. Therefore, the functional and signaling defects
observed in EphB2LacZ platelets may be explained through the loss
of direct signaling activity (kinase domain), disruption of the interaction
of the cytoplasmic tail with downstream signaling effector mole-
cules, or a combination of these. It may be possible that steric
constraints due to the introduction of a larger cytoplasmic tail may
also impact platelet function. Should this prove to be the case, it
would not diminish a key conclusion from this study: that the
cytoplasmic tail of EphB2 is required for the regulation of platelet
function. In general, Eph kinases and ephrin B family members
regulate their signaling events through several cellular effector pro-
teins in phosphorylation-dependent andphosphorylation-independent
manners.2 Although the phosphorylation-dependent signaling events
of Eph kinases rely on the cytoplasmic region including kinase and
SAM domains, phosphorylation-independent signaling is mainly
driven through the C terminus PDZ-bindingmotif. Many of the Eph
kinase effector molecules reported in other cell types are involved
in the regulation of cytoskeletal rearrangements and focal adhesions.2
Therefore, further studies are needed to identify and characterize
the effector molecules that are involved in Eph signaling in
platelets.
In summary, we reveal that Eph-ephrin signaling is not only re-
stricted to sustained contact-dependent signaling during throm-
bus formation and clot retraction, but in the absence of Eph-ephrin
ligation between platelets, EphB2 also contributes to initial plate-
let activation signals in a contact-independent manner. Further stud-
ies are required to dissect the selective roles of individual tyrosine
Figure 7. EphB2 regulates platelet function through modulating calcium mobilization, PI3K- and integrin aIIbb3-mediated signaling. EphB2 may directly and/or
indirectly influence the activation of PLC isoforms and thereby controls PI3K signaling. The consequences of these signaling events modulate the calcium mobilization,
integrin aIIbb3 mediated inside-out signaling, and granule secretion. Because EphB2 is physically associated with integrin aIIbb3, it may be involved in the regulation of
integrin aIIbb3 mediated outside-in signaling. a and d in small discs represent a and dense granules, respectively. The dotted lines indicate the predictive functions.
DAG, diacylglycerol; FCRg, Fc receptor g chain; GPCR, G-protein–coupled receptor; IP3, inositol 1,4,5-trisphosphate; IP3R, IP3 receptor; PIP2, phosphatidylinositol
4,5-bisphosphate; PKC, protein kinase C.
phosphorylation sites and speciﬁc intracellular domains of EphB2 in
the regulation of platelet function.
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